Privo Technologies Initiates Dosing in Clinical Trial for Oral Cavity Cancer Treatment
Privo Technologies, Inc. has commenced dosing the first patient in its clinical trial for PRV131, a nanoengineered intratumoral cisplatin injectable aimed at treating T1–T3 oral squamous cell carcinoma (OSCC). This trial, part of the Phase 1/2 Dose Escalation and Dose Optimization Run-In Study (Arm 3 of CLN-004), seeks to evaluate the safety, preliminary efficacy, tolerability, and pharmacokinetics of PRV131. The treatment is designed to shrink tumors before surgery, potentially improving surgical outcomes and preserving oral tissue. PRV131 delivers high concentrations of cisplatin directly to tumors, minimizing systemic exposure and aiming to reduce the morbidity associated with traditional surgical approaches. 
